FI831146L - Steriliserad plasma och plasmaderivat och foerfarande foer deras framstaellning - Google Patents

Steriliserad plasma och plasmaderivat och foerfarande foer deras framstaellning

Info

Publication number
FI831146L
FI831146L FI831146A FI831146A FI831146L FI 831146 L FI831146 L FI 831146L FI 831146 A FI831146 A FI 831146A FI 831146 A FI831146 A FI 831146A FI 831146 L FI831146 L FI 831146L
Authority
FI
Finland
Prior art keywords
och
plasma
plasmaderivat
sterilizers
factor viii
Prior art date
Application number
FI831146A
Other languages
English (en)
Other versions
FI831146A0 (fi
FI80211C (fi
FI80211B (fi
Inventor
Alfred Mayer Prince
Original Assignee
New York Blood Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23450479&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI831146(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by New York Blood Center Inc filed Critical New York Blood Center Inc
Publication of FI831146A0 publication Critical patent/FI831146A0/fi
Publication of FI831146L publication Critical patent/FI831146L/fi
Application granted granted Critical
Publication of FI80211B publication Critical patent/FI80211B/fi
Publication of FI80211C publication Critical patent/FI80211C/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0029—Radiation
    • A61L2/0035—Gamma radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088—Liquid substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Lubricants (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
FI831146A 1982-04-14 1983-04-05 Metod foer inaktivering av hepatit b virusin plasma och plasmaderivat. FI80211C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/368,250 US4481189A (en) 1982-04-14 1982-04-14 Process for preparing sterilized plasma and plasma derivatives
US36825082 1982-04-14

Publications (4)

Publication Number Publication Date
FI831146A0 FI831146A0 (fi) 1983-04-05
FI831146L true FI831146L (fi) 1983-10-15
FI80211B FI80211B (fi) 1990-01-31
FI80211C FI80211C (fi) 1990-05-10

Family

ID=23450479

Family Applications (1)

Application Number Title Priority Date Filing Date
FI831146A FI80211C (fi) 1982-04-14 1983-04-05 Metod foer inaktivering av hepatit b virusin plasma och plasmaderivat.

Country Status (13)

Country Link
US (1) US4481189A (fi)
EP (1) EP0099445B2 (fi)
JP (1) JPH0660105B2 (fi)
AT (1) ATE58835T1 (fi)
AU (1) AU561900B2 (fi)
CA (1) CA1207229A (fi)
DE (1) DE3382042D1 (fi)
DK (1) DK164537C (fi)
ES (1) ES8403722A1 (fi)
FI (1) FI80211C (fi)
NO (1) NO163514C (fi)
NZ (1) NZ203878A (fi)
ZA (1) ZA832239B (fi)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4581231A (en) * 1982-06-10 1986-04-08 The United States Of America As Represented By The Secretary Of Health And Human Services Inactivation of viruses containing essential lipids
CA1213827A (en) * 1983-04-29 1986-11-12 Ricardo H. Landaburu Process for pasteurizing fibronectin
US4764369A (en) * 1983-07-14 1988-08-16 New York Blood Center Inc. Undenatured virus-free biologically active protein derivatives
US4820805A (en) * 1983-07-14 1989-04-11 New York Blood Center, Inc. Undenatured virus-free trialkyl phosphate treated biologically active protein derivatives
US4615886A (en) * 1983-08-31 1986-10-07 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Utilizing a halohydrocarbon containing dissolved water to inactivate a lipid virus
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
EP0172716A1 (en) * 1984-08-14 1986-02-26 Shiley Incorporated Retarded mineralization of implantable tissue by surface active betaines
JPS61103836A (ja) * 1984-10-24 1986-05-22 Green Cross Corp:The フイブロネクチン製剤
US4613501A (en) * 1984-12-21 1986-09-23 New York Blood Center, Inc. Inactivation of viruses in labile blood derivatives
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4649192A (en) * 1985-05-30 1987-03-10 Smith Kline-Rit Method for the isolation and purification of hepatitis B surface antigen using polysorbate
US5281392A (en) * 1986-03-10 1994-01-25 Rubinstein Alan I Method for disinfecting red blood cells, blood products, and corneas
US5185371A (en) * 1986-03-10 1993-02-09 University Of Southern California Method for disinfecting red blood cells
US5211912A (en) * 1986-08-01 1993-05-18 University Of Southern California Method for disinfecting red blood cells, blood products, and corneas
US4971760A (en) * 1986-03-10 1990-11-20 University Of Southern California Novel method for disinfecting red blood cells, blood platelets, blood plasma, and optical corneas and sclerae
AT390374B (de) * 1986-03-18 1990-04-25 Schwab & Co Gmbh Verfahren zum pasteurisieren von plasmaprotein und plasmaproteinfraktionen
US4789545A (en) * 1986-03-31 1988-12-06 New York Blood Center, Inc. Removal of lipid soluble process chemicals from biological materials by extraction with naturally occurring oils or synthetic substitutes thereof
US4841023A (en) * 1986-06-25 1989-06-20 New York Blood Center, Inc. Inactivation of viruses in labile protein-containing compositions using fatty acids
US4749783A (en) * 1986-07-11 1988-06-07 Miles Laboratories, Inc. Viral inactivation and purification of active proteins
AU6942387A (en) * 1986-08-01 1988-03-24 Rubinstein, A.I. A method to treat blood
US4944920A (en) * 1986-08-01 1990-07-31 University Of Southern California Novel method to treat blood
DE3704550A1 (de) * 1987-02-13 1988-08-25 Behringwerke Ag Verfahren zur inaktivierung huellhaltiger viren in mittels einer zelle in vitro hergestellten protein-praeparationen
CA1339946C (en) * 1987-03-31 1998-07-07 Michael J. Griffith Ultrapurification process for polypeptides
US4869826A (en) * 1987-09-01 1989-09-26 Process Biotechnology, Inc. Cellular adsorbents for removal of viral contaminants from blood and complex protein solutions
DE3733181C1 (de) * 1987-10-01 1989-01-19 Biotest Pharma Gmbh Verfahren zur Herstellung eines hochreinen,virussicheren,biologisch aktiven Transferrinpraeparates
US4909940A (en) * 1987-12-30 1990-03-20 New York Blood Center, Inc. Extraction of process chemicals from labile biological mixtures with organic alcohols or with halogenated hydrocarbons
DE3805459A1 (de) * 1988-02-22 1989-08-31 Biotest Pharma Gmbh Verfahren zur sterilisation von blut, plasma, blut- und plasmaderivaten, zellsuspensionen oder dgl.
DE3826792C1 (fi) * 1988-08-06 1989-07-06 Biotest Pharma Gmbh, 6072 Dreieich, De
US5094960A (en) 1988-10-07 1992-03-10 New York Blood Center, Inc. Removal of process chemicals from labile biological mixtures by hydrophobic interaction chromatography
US4939176A (en) * 1988-12-20 1990-07-03 Miles Inc. Viral inactivation process
US5026686A (en) * 1989-02-01 1991-06-25 Washington University Antiviral peptides
US5202246A (en) * 1989-08-16 1993-04-13 Armour Pharmaceutical Company Treatment of immobilized matrices for preparation of pharmaceutical and biological products with anti-microbial agents to remove pyrogen-producing organisms and pyrogens
GB9110808D0 (en) * 1991-05-17 1991-07-10 Retroscreen Ltd Aids vaccine and method for its production
AT402891B (de) * 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
DE4125625C2 (de) * 1991-08-02 1999-12-02 Octapharma Ag Glarus Verfahren zur Herstellung von virusinaktivierten Immunglobulinlösungen
AT399818B (de) * 1992-04-24 1995-07-25 Immuno Ag Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation
CA2124690C (en) * 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
WO1994013329A1 (de) * 1992-12-16 1994-06-23 Immuno Aktiengesellschaft Verfahren zur herstellung eines virussicheren biologischen präparates
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
CA2165065A1 (en) * 1993-06-23 1995-01-05 Henrietta Margolis-Nunno System for viral inactivation of blood
DE69433759T2 (de) 1993-07-30 2005-03-31 Aruba International Pty. Ltd., Rocklea Plasmadelipidationssystem
HRP940645A2 (en) * 1993-10-06 1996-12-31 Immuno Ag Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained
FR2716111B1 (fr) * 1994-02-11 1996-11-08 Cogia Procédé de préparation d'une composition cosmétique ou alimentaire apte à être conservée, dispositif et composition de longue conservation.
US5486293A (en) * 1994-03-21 1996-01-23 Hemasure, Inc. Removal of small exogenous molecules from biological fluids
DE69512416T3 (de) † 1994-07-14 2011-12-15 Croix Rouge De Belgique Fibrinogenkonzentrate aus blutplasma, verfahren und anlage für ihre herstellung
AUPN030794A0 (en) 1994-12-22 1995-01-27 Aruba International Pty Ltd Discontinuous plasma or serum delipidation
FI952196A0 (fi) * 1995-05-08 1995-05-08 Suomen Punainen Risti Veripalv Framstaellning av immunoglobulin
AU5929896A (en) * 1995-05-26 1996-12-11 Sadeque S. Naficy Apparatuses and methods for treatment of blood
DE19528221C2 (de) * 1995-08-01 1998-10-22 Blutspendedienst Der Drk Lande Verfahren zur Herstellung eines virussicheren, therapeutischen Präparates aus Humanplasma
US20040053208A1 (en) * 1995-08-29 2004-03-18 V. I. TECHNOLOGIES, Inc. Methods to selectively inactivate parasites in biological compositions
US6369048B1 (en) 1998-01-12 2002-04-09 V.I. Technologies, Inc. Methods and compositions for inactivating viruses
CZ307715B6 (cs) 1999-02-22 2019-03-06 University Of Connecticut Způsob lyofilizace vodné farmaceutické formulace faktoru VIII prosté albuminu
US6436344B1 (en) * 1999-11-02 2002-08-20 American National Red Cross Method of inactivating pathogens
EP1250929A4 (en) * 1999-12-20 2004-12-29 Mitsubishi Pharma Corp BY POROUS MEMBRANE-TREATED, VIRUS-FREE PLASMA PROTEIN COMPOUND AND ITS MANUFACTURING PROCESS
CA2395435A1 (en) * 1999-12-22 2001-06-28 David B. Weiner Cosmid dna constructs and methods of making and using the same
AUPQ486699A0 (en) * 1999-12-23 2000-02-03 Aruba International Pty Ltd A method of treating infectious diseases
US7407663B2 (en) * 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified immunodeficiency virus particles
US20090017069A1 (en) 2000-06-29 2009-01-15 Lipid Sciences, Inc. SARS Vaccine Compositions and Methods of Making and Using Them
US7407662B2 (en) * 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified viral particles with immunogenic properties and reduced lipid content
US7439052B2 (en) 2000-06-29 2008-10-21 Lipid Sciences Method of making modified immunodeficiency virus particles
US6635679B2 (en) * 2001-05-14 2003-10-21 Akzo Nobel N.V. Methods and compositions for inactivating viruses
US6991727B2 (en) 2001-06-25 2006-01-31 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
US7033500B2 (en) * 2001-06-25 2006-04-25 Lipid Sciences, Inc. Systems and methods using multiple solvents for the removal of lipids from fluids
US20060060520A1 (en) 2001-06-25 2006-03-23 Bomberger David C Systems and methods using a solvent for the removal of lipids from fluids
US6893639B2 (en) * 2001-10-19 2005-05-17 Hemacare Corporation Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
US20030133829A1 (en) * 2001-12-21 2003-07-17 Baxter Healthcare Corporation Process for inactivating pathogens in a biological material
ES2453105T3 (es) * 2003-02-27 2014-04-04 Baxter International Inc. Dispositivo para la calibración en un método para la inactivación certificable de patógenos por irradiación en un fluido biológico
US7393826B2 (en) 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
WO2005011620A2 (en) 2003-07-03 2005-02-10 Lipid Sciences Inc. Methods and apparatus for creating particle derivatives of hdl with reduced lipid content
US6881573B2 (en) * 2003-09-12 2005-04-19 Allan L. Louderback Augmented solvent/detergent method for inactivating enveloped and non-enveloped viruses
CN102924565A (zh) 2004-06-07 2013-02-13 厄普弗朗特色谱公司 血浆或者血清蛋白的分离
US7993580B2 (en) * 2004-08-24 2011-08-09 Baxter International Inc. Methods for the inactivation of microorganisms in biological fluids, flow through reactors and methods of controlling the light sum dose to effectively inactivate microorganisms in batch reactors
EP1685852A1 (en) * 2005-02-01 2006-08-02 Fondation pour la Recherche Diagnostique Set of disposable bags for viral inactivation of biological fluids
US20090186395A1 (en) * 2006-06-26 2009-07-23 Israel Nur Virus Removal by Nanofiltration
GB0710321D0 (en) * 2007-05-30 2007-07-11 Nhs Blood & Transplant Method
US9956272B2 (en) 2007-05-30 2018-05-01 Bio Products Laboratory Limited Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same
EP2271374B1 (en) * 2008-03-28 2014-03-05 Research Foundation For Medical Devices Method of viral inactivation of biological fluids by solvent/detergent-treatment
TR201900207T4 (tr) 2008-11-07 2019-02-21 Baxalta GmbH Faktör VIII Formülasyonları
EP2399613A1 (en) 2010-06-22 2011-12-28 Research Foundation For Medical Devices Fractionation of plasma using caprylic acid
CN106138851A (zh) * 2016-09-08 2016-11-23 四川聚豪生物科技有限公司 一种可有效治疗乙肝的汤剂药物及其制备方法
US10821133B2 (en) 2017-12-28 2020-11-03 Hdl Therapeutics, Inc. Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma
CN111868232B (zh) 2017-11-22 2024-05-28 Hdl治疗公司 用于对血浆处理系统的流体回路进行灌注的系统和方法
AU2019387368A1 (en) 2018-11-30 2021-06-17 Cellphire, Inc. Platelets as delivery agents
SG11202112054WA (en) 2019-05-03 2021-11-29 Cellphire Inc Materials and methods for producing blood products
US20210069240A1 (en) * 2019-09-05 2021-03-11 Cellphire, Inc. Materials and methods for blood plasma preparations
CA3170196A1 (en) 2020-02-04 2021-08-12 Cellphire, Inc. Anti-fibrinolytic loaded platelets

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086218A (en) * 1975-04-11 1978-04-25 Edward Shanbrom, Inc. Method of preserving blood plasma II
GB1507215A (en) * 1975-08-19 1978-04-12 Green Cross Corp Processes for producing immunoregulatory preparations
US4057628A (en) * 1976-04-19 1977-11-08 William L. Wilson Removal of hepatitis associated antigen from plasma
US4222934A (en) * 1979-04-12 1980-09-16 American National Red Cross Preparation of albumin using ethanol
DE3176491D1 (en) * 1980-03-05 1987-11-26 Miles Lab Pasteurized therapeutically active protein compositions
US4305871A (en) * 1980-09-02 1981-12-15 Edward Shanbrom Method of selectively increasing yield and purity of certain cryoprecipitate proteins by heating
DE3033932C2 (de) 1980-09-10 1984-05-24 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Kaltsterilisation von Blutgerinnungsfaktor VIII enthaltenden Präparaten
US4315919A (en) * 1980-10-06 1982-02-16 Edward Shanbrom Depyrogenation process
DE3173208D1 (en) * 1980-10-06 1986-01-23 Edward Shanbrom Method of reducing undesirable activities of biological and pharmaceutical products
US4314997A (en) * 1980-10-06 1982-02-09 Edward Shanbrom Purification of plasma protein products

Also Published As

Publication number Publication date
ZA832239B (en) 1984-11-28
EP0099445B2 (en) 1998-07-08
FI831146A0 (fi) 1983-04-05
DK164537B (da) 1992-07-13
EP0099445B1 (en) 1990-12-05
US4481189A (en) 1984-11-06
EP0099445A3 (en) 1985-01-16
DE3382042D1 (de) 1991-01-17
NO831304L (no) 1983-10-17
DK164537C (da) 1992-11-30
AU561900B2 (en) 1987-05-21
ES521431A0 (es) 1984-04-01
FI80211C (fi) 1990-05-10
NO163514B (no) 1990-03-05
CA1207229A (en) 1986-07-08
NZ203878A (en) 1986-02-21
JPS58222023A (ja) 1983-12-23
AU1346283A (en) 1983-10-20
NO163514C (no) 1990-06-13
ATE58835T1 (de) 1990-12-15
ES8403722A1 (es) 1984-04-01
FI80211B (fi) 1990-01-31
JPH0660105B2 (ja) 1994-08-10
EP0099445A2 (en) 1984-02-01
DK162983A (da) 1983-10-15
DK162983D0 (da) 1983-04-13

Similar Documents

Publication Publication Date Title
FI831146L (fi) Steriliserad plasma och plasmaderivat och foerfarande foer deras framstaellning
US4613501A (en) Inactivation of viruses in labile blood derivatives
EP0131740B1 (en) Undenatured virus-free biologically active protein derivatives
ES8705764A1 (es) Procedimiento fotodinamico de inactivacion de virus
HU9201986D0 (en) A blood preparation inactivated to viruses
DE59813677D1 (de) Verfahren zur Inaktivierung von lipidumhüllten Viren
ES2083764T3 (es) Vacuna contra el sindrome respiratorio reproductivo porcino (srrp) y diagnostico.
DE69535758D1 (de) Lipid-analoge zur behandlung von viralen infektionen
Horowitz et al. Viral safety of solvent/detergent-treated blood products
ES8608577A1 (es) Un metodo para inactivar virus que contienen lipidos esen- ciales en un vehiculo proteinico seco
ES8503721A1 (es) "un metodo de inactivar un virus lipidico"
ES2123048T3 (es) Analogos de nucleosidos antiviricos.
ES2173923T3 (es) Procedimiento que permite inactivar un virus en presencia de un polieter y de un agente.
DE68923169D1 (de) Verwendung von fluor enthaltenden Pyridoncarbonsäure-Derivaten zur Herstellung eines Arzneimittels zur Behandlung von HIV infektionen.
ES8802579A1 (es) Procedimiento de obtencion de un aditivo concentrado para el ciclo de aclarado de lavavajillas
MX9301922A (es) Composiciones para el tratamiento de infeccion y enfermedad ocasionadas por el virus de hepatitis b (hbv).
YU57994A (sh) Postupak za inaktiviranje virusa u prisustvu polialkilenglikola i farmaceutski preparat dobijen tim postupkom
ATE115863T1 (de) Verwendung eines immunglobulinhaltigen präparates zur prophylaxe und therapie von aids beim menschen.
Soike et al. In vivo antiviral activity of recombinant type α interferon A in monkeys with infections due to simian varicella virus
FI881123A0 (fi) Inaktivering av human immunodeficiency virus (hiv) medelst fenol i proteinhaltiga loesningar.
DE69210737T2 (de) Verwendung von L-2-Oxothiazolidine-4-Carboxylate zur Herstellung eines Arzneimittels zur Behandlung von latenten HIV-Infektionen
Gerety Prevention of transmission of virus infections by blood transfusions and removal of virus infectivity from clotting factor concentrates
Morgenthaler Page/Contents/Preface/Abbreviations
SU1565027A1 (ru) Инактиватор вируса западного нила

Legal Events

Date Code Title Description
MA Patent expired

Owner name: NEW YORK BLOOD CENTER, INC.